Literature DB >> 12162403

Sildenafil improves right-ventricular parameters and quality of life in primary pulmonary hypertension.

A T Zimmermann, A F Calvert, E M Veitch.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12162403     DOI： 10.1046/j.1445-5994.2002.00258.x

Source DB:  PubMed          Journal:  Intern Med J        ISSN： 1444-0903            Impact factor:   2.048


× No keyword cloud information.
  5 in total

Review 1.  Recent advances in the treatment of systemic sclerosis.

Authors:  Vasiliki Kalliopi K Bournia; Panayiotis G Vlachoyiannopoulos; Carlo Selmi; Haralampos M Moutsopoulos; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

Review 2.  Drug treatment of pulmonary arterial hypertension: current and future agents.

Authors:  Marius M Hoeper
Journal:  Drugs       Date:  2005       Impact factor: 9.546

3.  Haemodynamic effects of the selective phosphodiesterase 5 inhibitor, UK-357,903, in conscious SHR.

Authors:  Sheila M Gardiner; Julie E March; Philip A Kemp; Stephen A Ballard; Ed Hawkeswood; Bernadette Hughes; Terence Bennett
Journal:  Br J Pharmacol       Date:  2003-12-08       Impact factor: 8.739

Review 4.  Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond.

Authors:  Hossein A Ghofrani; Ian H Osterloh; Friedrich Grimminger
Journal:  Nat Rev Drug Discov       Date:  2006-08       Impact factor: 84.694

Review 5.  Modulating cGMP to treat lung diseases.

Authors:  Hossein-Ardeschir Ghofrani; Friedrich Grimminger
Journal:  Handb Exp Pharmacol       Date:  2009
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.